Capital Fund Management S.A. Grows Stake in Progyny, Inc. (NASDAQ:PGNY)

Capital Fund Management S.A. raised its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 147.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 199,136 shares of the company's stock after acquiring an additional 118,604 shares during the quarter. Capital Fund Management S.A. owned approximately 0.23% of Progyny worth $3,435,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Signaturefd LLC lifted its position in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares during the period. Caitlin John LLC increased its holdings in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after acquiring an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Progyny during the 4th quarter worth approximately $74,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Performance

NASDAQ:PGNY traded up $0.04 during trading hours on Friday, reaching $21.44. The stock had a trading volume of 1,236,518 shares, compared to its average volume of 1,739,332. The stock has a market capitalization of $1.84 billion, a PE ratio of 36.97, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $33.84. The company has a 50 day moving average price of $21.96 and a two-hundred day moving average price of $18.81.

Analyst Ratings Changes

PGNY has been the subject of a number of recent analyst reports. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a research report on Monday, March 31st. Canaccord Genuity Group upped their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Bank of America raised their price target on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. increased their target price on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $23.64.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.